Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II mobilization and collection of CD34+ cells with Mozobil and Neupogen in Fanconi anaemia
2014-004272-29Phase 2Completed
- Sponsor
- Great Ormond Street Hospital
- Start
- Jul 2015
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plerixafor and filgrastim in Fanconi anemia (FA), sponsored by Great Ormond Street Hospital. Primary endpoint: Safety of CD34+ cell mobilization. Started Jul 2015; status: completed.
02
Drugs
plerixaforfilgrastim
03
Conditions
Fanconi anemia (FA)
Beyond the preview
Go deeper on 2014-004272-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004272-29.